Tags

Type your tag names separated by a space and hit enter

Role of hyperthermia in the treatment of Peyronie's disease: a preliminary study.
Int J Hyperthermia. 2005 Jun; 21(4):367-74.IJ

Abstract

OBJECTIVE

Previous experience in the treatment of plaque with hyperthermia in orthopaedics led the authors to investigate the effectiveness of this approach in patients with Peyronie's disease.

PATIENTS AND METHODS

The study population comprised 60 patients (aged 36-76 years) with advanced Peyronie's disease. Patients were divided into two groups (A and B), with 30 in each. Group A patients underwent local hyperthermia treatment, with 30-min treatment sessions twice a week for 5 weeks. Patients received a total of 10 applications, which reached a local temperature of 39-40 degrees C. A second cycle was repeated after a 1-month interval for a total of 20 treatment sessions. Group B patients were treated with intra-plaque infiltrations using 10 mg verapamil; they received one infiltration once a week for 3 months. Differences between the two groups, as well as between variables (before and after treatment), were analysed using Student t-test and Fisher test.

RESULTS

Hyperthermia significantly reduced plaque size and penile curvature and led to an increase in mean scores of erectile function (EF) domain, while verapamil had no such effects. Haemodynamic parameters were not significantly modified in either group. Hyperthermia caused significantly fewer side effects than verapamil infiltrations and was significantly more effective in preventing disease progression. There were no significant differences between the two groups in terms of pain reduction during erection.

CONCLUSIONS

Results of this study stress the efficacy of hyperthermia in the treatment of advanced Peyronie's disease.

Authors+Show Affiliations

Department of Urology, University of Rome La Sapienza, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

16019862

Citation

Perugia, G, et al. "Role of Hyperthermia in the Treatment of Peyronie's Disease: a Preliminary Study." International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, vol. 21, no. 4, 2005, pp. 367-74.
Perugia G, Liberti M, Vicini P, et al. Role of hyperthermia in the treatment of Peyronie's disease: a preliminary study. Int J Hyperthermia. 2005;21(4):367-74.
Perugia, G., Liberti, M., Vicini, P., Colistro, F., & Gentile, V. (2005). Role of hyperthermia in the treatment of Peyronie's disease: a preliminary study. International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 21(4), 367-74.
Perugia G, et al. Role of Hyperthermia in the Treatment of Peyronie's Disease: a Preliminary Study. Int J Hyperthermia. 2005;21(4):367-74. PubMed PMID: 16019862.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of hyperthermia in the treatment of Peyronie's disease: a preliminary study. AU - Perugia,G, AU - Liberti,M, AU - Vicini,P, AU - Colistro,F, AU - Gentile,V, PY - 2005/7/16/pubmed PY - 2005/11/9/medline PY - 2005/7/16/entrez SP - 367 EP - 74 JF - International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group JO - Int J Hyperthermia VL - 21 IS - 4 N2 - OBJECTIVE: Previous experience in the treatment of plaque with hyperthermia in orthopaedics led the authors to investigate the effectiveness of this approach in patients with Peyronie's disease. PATIENTS AND METHODS: The study population comprised 60 patients (aged 36-76 years) with advanced Peyronie's disease. Patients were divided into two groups (A and B), with 30 in each. Group A patients underwent local hyperthermia treatment, with 30-min treatment sessions twice a week for 5 weeks. Patients received a total of 10 applications, which reached a local temperature of 39-40 degrees C. A second cycle was repeated after a 1-month interval for a total of 20 treatment sessions. Group B patients were treated with intra-plaque infiltrations using 10 mg verapamil; they received one infiltration once a week for 3 months. Differences between the two groups, as well as between variables (before and after treatment), were analysed using Student t-test and Fisher test. RESULTS: Hyperthermia significantly reduced plaque size and penile curvature and led to an increase in mean scores of erectile function (EF) domain, while verapamil had no such effects. Haemodynamic parameters were not significantly modified in either group. Hyperthermia caused significantly fewer side effects than verapamil infiltrations and was significantly more effective in preventing disease progression. There were no significant differences between the two groups in terms of pain reduction during erection. CONCLUSIONS: Results of this study stress the efficacy of hyperthermia in the treatment of advanced Peyronie's disease. SN - 0265-6736 UR - https://wwww.unboundmedicine.com/medline/citation/16019862/Role_of_hyperthermia_in_the_treatment_of_Peyronie's_disease:_a_preliminary_study_ L2 - https://www.tandfonline.com/doi/full/10.1080/02656730500133892 DB - PRIME DP - Unbound Medicine ER -